Global Stock News

Moderna touts its COVID vaccine’s endurance and earnings that beat expectations

Article feature image

Moderna touts its COVID vaccine’s endurance and earnings that beat expectations

Moderna Inc. said its COVID-19 vaccine remained 93% effective six months after the second shot as it reported second-quarter earnings and revenue that beat expectations.
A final analysis of the companys late-stage study, described in a statement on Thursday,…

Click here to view the original article.

Share this article

Scroll to Top